Back to School: How biopharma can reboot drug development. Access exclusive analysis here

UK-279,276 (rNIF): Began Phase IIb trial

Corvas International Inc. (CVAS), San Diego,

Read the full 63 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE